Mirador Therapeutics, Inc.
Clinical trials sponsored by Mirador Therapeutics, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a new drug pair safely with a known Anti-Inflammatory? a trial investigates Results expected Nov 2026 (estimated)
- New drug MT-201 tested in humans for first time Results expected Nov 2026 (estimated)
- New drug MT-251 tested in healthy people for first time Results expected Mar 2027 (estimated)
- New hope for IBD sufferers: two experimental drugs enter Mid-Stage trial Results expected Apr 2027 (estimated)
-
New drug MT-701 passes early safety check in healthy people
Knowledge-focused CompletedThis early-stage study tested the safety of a new drug called MT-701 in 46 healthy adults aged 19 to 55. Participants received either the drug or a placebo, and researchers monitored for side effects and how the drug moved through the body. The goal was not to treat any disease, …
Phase 1 • Sponsor: Mirador Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
New drug MT-501 takes first step: safety check in healthy people
Knowledge-focused CompletedThis early-phase trial tested the safety and tolerability of a new drug called MT-501 in 72 healthy adults aged 19 to 55. Participants received either single or multiple oral doses of MT-501 or a placebo. The main goal was to monitor for side effects and how the drug moves throug…
Phase 1 • Sponsor: Mirador Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC